Evidence map›Paper›PMID 40646556›Full record

ArticleTrials2025

Validation of new diagnostic indices to simplify hyponatremia therapy assessment in patients on thiazide diuretics: study protocol of a randomized, controlled, parallel-group trial (THAT-Study).

Karin Vogt, David Widmer, Mark Kirsch, Mirjam Christ-Crain, Laura Potasso

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06381934 (Validation of Diagnostic Indices to Simplify Hyponatremia Therapy Assessment - A Randomized, Controlled, Parallel-group Clinical Trial in Hospitalized Patients on Thiazide Diuretics), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06381934 narecruitingnot on this map

Validation of Diagnostic Indices to Simplify Hyponatremia Therapy Assessment - A Randomized, Controlled, Parallel-group Clinical Trial in Hospitalized Patients on Thiazide Diuretics (THAT Study)

TypeinterventionalSponsorUniversity Hospital, Basel, SwitzerlandRan2024 to 2027Enrolled136ConditionsThiazide Associated HyponatremiaArmsStandard Care, aSID/ChU Guided Therapy
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karin VogtDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. karin.vogt@usb.ch.ORCID http://orcid.org/0009-0002-1749-1048
David WidmerDivision of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Mark KirschDivision of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Mirjam Christ-CrainDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
Laura PotassoDepartment of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. laura.potasso@usb.ch.

Funding

Margot und Erich Goldschmidt und Peter René Jacobson-Stiftung 2024
6 · The paper itself

Abstract

backgroundThiazide or thiazide-like diuretics associated hyponatremia (TAH) has a high prevalence in hospitalized patients. Patients might present either with hypovolemic hyponatremia due to volume loss as a diuretic effect of thiazide or with a thiazide-induced syndrome of inadequate antidiuresis-like hyponatremia in need of fluid restriction. Sodium-based urine indices are usually not able to differentiate these two, being directly influenced by thiazide itself. Current guidelines suggest the use of clinical hydration status assessment in patients with TAH, but this approach has a poor diagnostic performance. In a retrospective analysis, we found apparent strong ion difference (aSID) as well as chloride and potassium levels in urine (ChU) to be helpful in the differential diagnosis of TAH.

methodsThis is a randomized (1:1 ratio) controlled, superiority, parallel-group single-center trial. In total, 136 participants with TAH < 130 mmol/l will be enrolled and randomly assigned to undergo either aSID/ChU-guided therapy of TAH or standard of care during hospitalization. At baseline, hydration status will be assessed by history/clinical examination and ultrasound. The primary outcome is the percentage of patients with an increase in serum sodium level > 4 mmol/l at day 1 or > 134 mmol/l in a maximum of 3 days in the aSID/ChU guided therapy group as compared to the standard care group. DISCUSSION: This study will prospectively investigate whether the implementation of 2 new diagnostic indices (aSID and, if inconclusive, ChU) allows for a correct treatment of TAH. As a secondary outcome, the performance of clinical and ultrasound-guided hydration status assessment will be investigated.

trial registrationClinicalTrials.gov, identifier: NCT06381934 . Registered on 19 April 2024. www.kofam.ch , identifier: SNCTP 000005848/BASEC2024-00335.

Indexed as

HyponatremiaSodium Chloride Symporter InhibitorsChloridesEquivalence Trials as TopicHumansMaleOrganism Hydration StatusPotassiumPredictive Value of TestsRandomized Controlled Trials as TopicSodiumTreatment OutcomeChloridesPotassiumSodiumSodium Chloride Symporter InhibitorsASIDHydration statusPOCUSPoint-of-care ultrasoundSodiumStewart modelThiazide-associated hyponatremiaVolume status

Identifiers

PMID40646556
PMCPMC12247219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.